Phase 2 Obesity Trial, Recruiting NCT07243171 Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. Condition: Obesity
Back to Obesity

Phase 2 Obesity Trial, Recruiting

NCT07243171
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your Body Mass Index (BMI) must be between 24.0 and 35.0 at the time of joining, AND you must weigh more than 60 kg (about 132 lbs) if male, or more than 50 kg (about 110 lbs) if female
  • Your body weight must not have changed by more than 5% in the 3 months before joining (self-reported)

Who may not be able to join:

  • People whose excess weight is caused by a hormonal or gland-related condition, such as Cushing's syndrome
  • People diagnosed with certain thyroid or hormonal conditions, including an overactive or underactive thyroid, certain thyroid nodules, thyroid cancer, or a personal or family history of a condition called Type 2 Multiple Endocrine Neoplasia (MEN2) (confirm with trial site)
  • People who have had a significant heart or stroke-related event in the 6 months before screening, such as a stroke, heart attack, heart failure, or irregular heartbeat
  • People with serious digestive or gut conditions, such as inflammatory bowel disease, active ulcers, irritable bowel syndrome, celiac disease, or problems with how the stomach empties food (confirm with trial site for full list)
  • People who have had major surgery on their digestive system in the past (removal of the gallbladder or appendix is generally okay), or who plan to have major surgery during the study
  • People whose blood sugar levels are too high, which may indicate diabetes — this is checked through specific blood tests at screening (confirm with trial site for exact values)
  • People whose routine blood test results show results of medical concern at screening (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Registry
ClinicalTrials.gov
Start date
18 November 2025
Est. completion
3 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The incidence and severity of adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov